权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A mucosally targeted MERS-CoV vaccine produced in plants

在植物中生产的粘膜靶向 MERS-CoV 疫苗

基本信息

批准号：
9141182
负责人：
KEITH WYCOFF
金额：
$ 23.65万
依托单位：
PLANET BIOTECHNOLOGY, INC.
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-02-17 至 2018-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9141182
关键词：
Acute Amino Acid Sequence Amino Acids Animals Antibodies Antigen Presentation Antigen-Presenting Cells Binding Camels Case Study Cell Culture Techniques Cells Cellular Immunity Cessation of life Chimeric Proteins Contracts Coronavirus Coronavirus spike protein Country Development Dipeptidyl Peptidases Epidemic Fatality rate Fc Receptor Fc domain Flow Cytometry Human IgG1 Immune response Immunization Immunize In Vitro Kilogram Mammalian Cell Measures Mediating Middle East Middle East Respiratory Syndrome Coronavirus Modification Molecular Biology Mucosal Immune Responses Mus Phase Plants Play Process Production Proteins Recombinant Fusion Proteins Recombinant Proteins Reporting Research Role Saudi Arabia Small Business Innovation Research Grant Staining method Stains Surface System T cell response Testing Therapeutic Time Vaccine Design Vaccines Variant Viral Virus Virus Receptors World Health Organization antigen binding cost cytokine epidemiology study immunogenicity improved in vivo milligram mortality neonatal Fc receptor neutralizing antibody pandemic disease public health relevance receptor binding residence respiratory trafficking transmission process vaccine candidate

项目摘要

DESCRIPTION (provided by applicant): Middle East Respiratory Syndrome (MERS) coronavirus (MERS-CoV) causes severe acute respiratory illness with a high fatality rate among reported cases. MERS was first reported in 2012, but the virus has been circulating in camels, which are thought to be an animal reservoir, for at least 20 years. To date over 1000 MERS cases have been reported to the World Health Organization, including over 400 deaths. While most cases have been in Saudi Arabia and contact with camels or camel products has been implicated in some cases, human-to-human transmission has been documented as well and the virus is thought to have epidemic potential. There are currently no approved vaccines or therapeutics for MERS. The MERS-CoV spike (S) protein mediates viral entry into host cells expressing the viral receptor dipeptidyl peptidase 4 (DPP4). Within the S1 subunit, a Receptor Binding Domain (RBD) of about 200 amino acids has been identified. Immunization of mice with a recombinant fusion protein containing S377-588 fused to human IgG1 Fc (S377-588-Fc) induced high titers of neutralizing antibodies in immunized animals. Unfortunately, expression of S377-588-Fc (or RBD-Fc) in mammalian cell culture is low, which may be an impediment for further development of this promising candidate vaccine. We will circumvent the production problem by producing MERS-CoV RBD-Fc, and modifications thereof, using a well-established plant-expression system. Our scalable transient plant-expression system allows rapid production of recombinant protein (within a week); with protein production costs less than 10% that of mammalian cell systems. We will produce variants of MERS-CoV RBD-Fc with enhanced binding to the mouse neonatal Fc receptor (FcRn), in order to test the hypothesis that improved antigen presentation via FcRn will result in an enhanced immune response. We will evaluate the immunogenicity of mucosally-administered MERS-CoV RBD-Fc in mice, by analyzing both humoral and cell-mediated immunity. We will evaluate titers of RBD-specific antibodies, analyze T cell responses by intracellular cytokine staining followed by flow cytometry analysis, and will measure the ability of sera from immunized mice to neutralize live MERS-CoV in vitro.